• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Protagonist Therapeutics Inc. (Amendment)

    2/2/24 9:19:56 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTGX alert in real time by email
    SC 13G/A 1 ptgx_13ga.htm
       
       
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.  6)   *


    Protagonist Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
     
    74366E102
    (Cusip Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    S
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    (Continued on following pages)
    Page 1 of 37 Pages
    Exhibit Index Found on Page 36


    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    386,653 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    386,653 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    386,653 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.7% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 5,676 Shares for which Warrants are exercisable within the next 60 days.  Excludes 271,824 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 2 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    396,682 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    396,682 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    396,682 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.7% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 5,982 Shares for which Warrants are exercisable within the next 60 days.  Excludes 286,518 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 3 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    127,386 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    127,386 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    127,386 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.2% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 1,074 Shares for which Warrants are exercisable within the next 60 days.  Excludes 51,426 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 4 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners III, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    54,391 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    54,391 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    54,391 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 691 Shares for which Warrants are exercisable within the next 60 days.  Excludes 33,109 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 5 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Four Crossings Institutional Partners V, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    71,920 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    71,920 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    71,920 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    2 Includes 920 Shares for which Warrants are exercisable within the next 60 days.  Excludes 44,080 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 6 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Offshore Investors II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    764,635 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    764,635 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    764,635 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.3% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    3 Includes 14,599 Shares for which Warrants are exercisable within the next 60 days.  Excludes 699,215 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 7 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital (AM) Investors, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    49,886 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    49,886 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    49,886 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    4 Includes 307 Shares for which Warrants are exercisable within the next 60 days.  Excludes 14,693 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 8 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital F5 Master I, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    166,799 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    166,799 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    166,799 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.3% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    5 Includes 1,429 Shares for which Warrants are exercisable within the next 60 days.  Excludes 68,457 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 9 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners Master, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    3,746,756
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    3,746,756
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,746,756
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.5%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 10 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Partners, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    5,598,310 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    5,598,310 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,598,310 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.7% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    6 Includes 29,250 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,400,864 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 11 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Institutional (GP) V, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    71,920 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    71,920 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    71,920 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    7 Includes 920 Shares for which Warrants are exercisable within the next 60 days.  Excludes 44,080 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 12 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon F5 (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    166,799 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    166,799 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    166,799 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.3% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    8 Includes 1,429 Shares for which Warrants are exercisable within the next 60 days.  Excludes 68,457 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 13 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    3,746,756
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    3,746,756
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,746,756
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.5%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO



    Page 14 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Joshua J. Dapice
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    9 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 15 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Philip D. Dreyfuss
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    10 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 16 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Hannah E. Dunn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    11 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 17 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael B. Fisch [See Item 2]
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    -0-
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    -0-
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    -0-
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 18 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Richard B. Fried
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    12 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 19 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Varun N. Gehani
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    13 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 20 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Nicolas Giauque
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    France
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    14 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 21 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    David T. Kim
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    15 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 22 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael G. Linn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    16 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 23 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Rajiv A. Patel
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    17 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 24 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Thomas G. Roberts, Jr.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    18 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 25 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Edric C. Saito
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    19 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 26 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    William Seybold
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    20 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 27 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Daniel S. Short
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    21 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 28 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Andrew J. M. Spokes
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    22 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 29 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    John R. Warren
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109  1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109  1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109  1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    23 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 30 of 37 Pages

    13G
    CUSIP No. 74366E102
     

    1
    NAMES OF REPORTING PERSONS
     
    Mark C. Wehrly
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares.  Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
     5,765,109 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
     5,765,109 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     5,765,109 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    24 Includes 30,679 Shares for which Warrants are exercisable within the next 60 days.  Excludes 1,469,321 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).


    Page 31 of 37 Pages


    This Amendment No. 6 to Schedule 13G amends and restates in its entirety the Schedule 13G initially filed on August 20, 2018 (together with all prior and current amendments thereto, this “Schedule 13G”).

    Preliminary Note:

    As of the date of this report, the Farallon Funds hold an aggregate of: (i) 5,734,430 Shares; and (ii) 1,500,000 Common Stock Purchase Warrants (the “Warrants”), each of which currently is exercisable, pursuant to the terms thereof, to purchase one Share.

    The terms of the Warrants provide that Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the Shares then issued and outstanding (the “Beneficial Ownership Limitation”).  As of the date hereof, the Beneficial Ownership Limitation permits the Farallon Funds to exercise Warrants for an aggregate of not more than 30,679 Shares.  In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining 1,469,321 Warrants held by the Farallon Funds are not exercisable due to the Beneficial Ownership Limitation.

    Capitalized terms used in this Preliminary Note without definitions have the meanings ascribed to them below.

    Item 1.
    Issuer

    (a) Name of Issuer:

    Protagonist Therapeutics, Inc. (the “Company”)

    (b) Address of Issuer’s Principal Executive Offices:

    7707 Gateway Blvd., Suite 140
    Newark, CA 94560

    Item 2.
    Identity and Background

    Title of Class of Securities and CUSIP Number (Items 2(d) and (e))

    This statement relates to shares of Common Stock, par value $0.00001 per share (the “Shares”), of the Company.  The CUSIP number of the Shares is 74366E102.

    Name of Persons Filing, Address of Principal Business Office and Citizenship (Items 2(a), (b) and (c))

    This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”.

    The Farallon Funds
     
    (i)
                  Farallon Capital Partners, L.P., a California limited partnership (“FCP”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (ii)
                  Farallon Capital Institutional Partners, L.P., a California limited partnership (“FCIP”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (iii)
      Farallon Capital Institutional Partners II, L.P., a California limited partnership (“FCIP II”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (iv)
      Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership (“FCIP III”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (v)
                  Four Crossings Institutional Partners, L.P., a Delaware limited partnership (“FCIP V”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (vi)
      Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership (“FCOI II”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (vii)
     Farallon Capital (AM) Investors, L.P., a Delaware limited partnership (“FCAMI”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants;

    (viii)
    Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership (“F5MI”), with respect to the Shares held by it and the Shares that as of the date hereof it has the right to acquire upon the exercise of Warrants; and

    (ix)
      Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership (“FHPM”), with respect to the Shares held by it.

    FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the “Farallon Funds.”


    Page 32 of 37 Pages


    The Farallon General Partner

    (x)
                Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner”), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and (ii) the sole member of each of the FCIP V General Partner (as defined below) and the FHPM General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI and the Shares that as of the date hereof each of the Farallon Funds other than F5MI has the right to acquire upon the exercise of Warrants.

    The FCIP V General Partner

    (xi)
    Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner”), which is the general partner of FCIP V, with respect to the Shares held by FCIP V and the Shares that as of the date hereof  FCIP V has the right to acquire upon the exercise of Warrants.

    The F5MI General Partner

    (xii)
    Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner”), which is the general partner of F5MI, with respect to the Shares held by F5MI and the Shares that as of the date hereof  F5MI has the right to acquire upon the exercise of Warrants.

    The FHPM General Partner

    (xiii)
    Farallon Healthcare Partners (GP), L.L.C., a Delaware limited liability company (the “FHPM General Partner”), which is the general partner of FHPM, with respect to the Shares held by FHPM.

    The Farallon Individual Reporting Persons

    (xiv)
    The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, with respect to the Shares held by the Farallon Funds and the Shares that as of the date hereof the Farallon Funds have the right to acquire upon the exercise of Warrants:  Joshua J. Dapice (“Dapice”); Philip D. Dreyfuss (“Dreyfuss”); Hannah E. Dunn (“Dunn”); Richard B. Fried (“Fried”); Varun N. Gehani (“Gehani”); Nicolas Giauque (“Giauque”); David T. Kim (“Kim”); Michael G. Linn (“Linn”); Rajiv A. Patel (“Patel”); Thomas G. Roberts, Jr. (“Roberts”); Edric C. Saito (“Saito”); William Seybold (“Seybold”); Daniel S. Short (“Short”); Andrew J. M. Spokes (“Spokes”); John R. Warren (“Warren”); and Mark C. Wehrly (“Wehrly”).

    Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the “Farallon Individual Reporting Persons.”

    This Schedule 13G reports that effective June 30, 2023, Michael B. Fisch (“Fisch”) resigned as a member of the Farallon General Partner, a manager of the FCIP V General Partner, a manager of the F5MI General Partner and a manager of the FHPM General Partner.  Accordingly, as of that date, Fisch no longer may be deemed a beneficial owner of any Shares or Warrants held by the Farallon Funds.  Unless the context otherwise requires, any reference herein to the “Farallon Individual Reporting Persons” shall not include Fisch.

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is set forth above.  Each of Fisch and the Farallon Individual Reporting Persons, other than Giauque and Spokes, is a citizen of the United States.  Giauque is a citizen of France.  Spokes is a citizen of the United Kingdom.  The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.


    Page 33 of 37 Pages


    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c),         Check Whether the Person Filing Is an Entity Specified in (a) - (k):

    Not applicable.

    Item 4.
    Ownership

    The information required by Items 4(a) – (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    The Shares and Warrants reported hereby for the Farallon Funds are owned directly by the Farallon Funds. The Farallon General Partner, as general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares and Warrants owned by the Farallon Funds other than F5MI.  The FCIP V General Partner, as general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares and Warrants owned by FCIP V. The F5MI General Partner, as general partner of F5MI, may be deemed to be a beneficial owner of all such Shares and Warrants owned by F5MI.  The FHPM General Partner, as general partner of FHPM, may be deemed to be a beneficial owner of all such Shares owned by FHPM.  Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares and Warrants owned by the Farallon Funds.  Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares and Warrants.

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following:

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     Not applicable.

    Item 8.
    Identification and Classification of Members of the Group

    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c).  Consistent with Item 2 of the cover page for each Reporting Person above, the Reporting Persons neither disclaim nor affirm the existence of a group among them.

    Item 9.
    Notice of Dissolution of Group

    Not applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    Page 34 of 37 Pages


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 2, 2024

     
    /s/ Hannah E. Dunn
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By Hannah E. Dunn, Managing Member
       
     
    /s/ Hannah E. Dunn
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    Hannah E. Dunn, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly

    The Powers of Attorney executed by each of Dapice, Dreyfuss, Fisch, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly authorizing Dunn to sign and file this Schedule 13G on his behalf, which were filed as exhibits to the Schedule 13G filed with the Securities and Exchange Commission on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.


    Page 35 of 37 Pages


    EXHIBIT INDEX


    EXHIBIT 1
    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
     


    Page 36 of 37 Pages

    EXHIBIT 1
    to
    SCHEDULE 13G

    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

    Dated:  February 2, 2024

     
    /s/ Hannah E. Dunn
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By Hannah E. Dunn, Managing Member
       
     
    /s/ Hannah E. Dunn
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    Hannah E. Dunn, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly


    Page 37 of 37 Pages
    Get the next $PTGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTGX

    DatePrice TargetRatingAnalyst
    9/17/2025$72.00Overweight
    Barclays
    9/12/2025$73.00Outperform
    Leerink Partners
    6/17/2025$72.00Buy
    Citigroup
    12/6/2024$47.00Neutral
    Goldman
    12/6/2024$62.00Outperform
    BMO Capital Markets
    11/5/2024$58.00Outperform
    Wedbush
    9/24/2024$65.00Buy
    TD Cowen
    9/9/2024$60.00Buy
    Truist
    More analyst ratings

    $PTGX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

    2/10/26 11:19:49 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    2/6/26 4:10:02 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    1/30/26 2:43:24 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

    Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda ((TAK) and Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist") announced the submission of a New Drug Application (NDA)

    1/5/26 7:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

    52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints Patients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52 Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies

    12/6/25 9:30:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

    Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

    6/1/25 8:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Protagonist Therapeutics with a new price target

    Barclays initiated coverage of Protagonist Therapeutics with a rating of Overweight and set a new price target of $72.00

    9/17/25 8:03:08 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Protagonist Therapeutics with a new price target

    Leerink Partners initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $73.00

    9/12/25 7:52:34 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Protagonist Therapeutics with a new price target

    Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

    6/17/25 7:50:36 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Waddill William D. exercised 20,000 shares at a strike of $8.31 and sold $1,673,600 worth of shares (20,000 units at $83.68) (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    2/6/26 4:38:54 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Patel Dinesh V Ph D gifted 6,000 shares, exercised 48,273 shares at a strike of $10.79 and sold $4,063,743 worth of shares (48,273 units at $84.18), decreasing direct ownership by 1% to 574,505 units (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    1/27/26 9:21:26 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Ali Asif exercised 28,000 shares at a strike of $16.18 and sold $3,841,037 worth of shares (46,203 units at $83.13), decreasing direct ownership by 23% to 60,320 units (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    1/27/26 9:20:42 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTGX
    Leadership Updates

    Live Leadership Updates

    View All

    Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

    Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

    7/31/24 9:15:00 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist Therapeutics Set to Join S&P SmallCap 600

    NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

    6/27/24 5:44:00 PM ET
    $PTGX
    $SPGI
    $WIRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $PTGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/14/24 4:27:37 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/12/24 4:51:49 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/4/24 1:22:14 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTGX
    Financials

    Live finance-specific insights

    View All

    Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

    Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

    6/1/25 8:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

    − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

    3/3/25 6:45:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

    Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL

    11/21/24 4:05:00 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care